Melasma (Chlosma) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Melasma (Chlosma) – Pipeline Review, H2 2016’, provides an overview of the Melasma (Chlosma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melasma (Chlosma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Melasma (Chlosma)

The report reviews pipeline therapeutics for Melasma (Chlosma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Melasma (Chlosma) therapeutics and enlists all their major and minor projects

The report assesses Melasma (Chlosma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Melasma (Chlosma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Melasma (Chlosma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melasma (Chlosma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

EpiPharm AG

Hyundai Pharmaceutical Co Ltd

RXi Pharmaceuticals Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Melasma (Chlosma) Overview 5

Therapeutics Development 6

Pipeline Products for Melasma (Chlosma) - Overview 6

Melasma (Chlosma) - Therapeutics under Development by Companies 7

Melasma (Chlosma) - Pipeline Products Glance 8

Clinical Stage Products 8

Early Stage Products 9

Melasma (Chlosma) - Products under Development by Companies 10

Melasma (Chlosma) - Companies Involved in Therapeutics Development 11

EpiPharm AG 11

Hyundai Pharmaceutical Co Ltd 12

RXi Pharmaceuticals Corp 13

Melasma (Chlosma) - Therapeutics Assessment 14

Assessment by Monotherapy Products 14

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

EPI-M13 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

NPH-29 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

tranexamic acid - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

TRY-26071 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

TRY-26077 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Melasma (Chlosma) - Dormant Projects 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

List of Tables

List of Tables

Number of Products under Development for Melasma (Chlosma), H2 2016 6

Number of Products under Development by Companies, H2 2016 7

Comparative Analysis by Clinical Stage Development, H2 2016 8

Comparative Analysis by Early Stage Development, H2 2016 9

Products under Development by Companies, H2 2016 10

Melasma (Chlosma) – Pipeline by EpiPharm AG, H2 2016 11

Melasma (Chlosma) – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2016 12

Melasma (Chlosma) – Pipeline by RXi Pharmaceuticals Corp, H2 2016 13

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Stage and Target, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Melasma (Chlosma) – Dormant Projects, H2 2016 28

List of Figures

List of Figures

Number of Products under Development for Melasma (Chlosma), H2 2016 6

Number of Products under Development by Companies, H2 2016 7

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Targets, H2 2016 15

Number of Products by Stage and Targets, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports